HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation’s (NASDAQ: NYMX) NicAlert™ product has gained acceptance as an important tool in research studies and clinical trials where it is important to know the level of tobacco use or exposure among participants. Recent peer-reviewed publications of studies involving NicAlert™ include BMC Oral Health (June, 2008; 3; 8:18) [large scale study of oral health in Appalachia], Biol Psychiatry (June 2008; 63:1061–1065) [psychological effects of nicotine administered to nonsmokers], Psychopharma-cology (Berl) (July, 2008;199:89-98) and Neuropsychopharmacology (February 2008; 33:480–490) [cognitive effects of nicotine administered to nonsmokers], Am J Prev Med. (2007; 33:297-305) [monitoring NRT in smoking cessation research involving pregnant women], and Int J Behav Med. (2006; 13:16-25) [study of smoking rates in cancer patients). Many research institutions use NicAlert™ such as Harvard and the NIH.
